{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:51:08Z","timestamp":1785909068774,"version":"3.56.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","award":["6-2023-0146"],"award-info":[{"award-number":["6-2023-0146"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clml.2026.05.010","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:38:42Z","timestamp":1779899922000},"page":"e1017-e1025.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Autoimmune Features in Myelodysplastic Syndromes: Clinical and Molecular Heterogeneity With Integrated IPSS-M Analysis"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4848-668X","authenticated-orcid":false,"given":"Yoonseo","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.clml.2026.05.010_bib0001","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJMra1904794","article-title":"Myelodysplastic syndromes","volume":"383","author":"Cazzola","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2026.05.010_bib0002","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2016.112","article-title":"The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia","volume":"17","author":"Sperling","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2026.05.010_bib0003","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.critrevonc.2017.12.013","article-title":"Immune dysregulation in myelodysplastic syndrome: clinical features, pathogenesis and therapeutic strategies","volume":"122","author":"Wang","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"10.1016\/j.clml.2026.05.010_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071532","article-title":"Autoimmune complications in hematologic neoplasms","volume":"13","author":"Barcellini","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.clml.2026.05.010_bib0005","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1016\/S2352-3026(22)00138-7","article-title":"Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?","volume":"9","author":"Hochman","year":"2022","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.clml.2026.05.010_bib0006","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.leukres.2013.04.007","article-title":"Myelodysplastic syndromes and autoimmune diseases\u2013case series and review of literature","volume":"37","author":"Al Ustwani","year":"2013","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.clml.2026.05.010_bib0007","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hon.2423","article-title":"The burden of autoimmunity in myelodysplastic syndromes","volume":"36","author":"Fozza","year":"2018","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.05.010_bib0008","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.autrev.2018.07.009","article-title":"Autoimmune diseases in myelodysplastic syndrome favors patients survival: a case control study and literature review","volume":"18","author":"Seguier","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"21","key":"10.1016\/j.clml.2026.05.010_bib0009","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1200\/JCO.2011.34.8540","article-title":"Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes","volume":"29","author":"Kristinsson","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2026.05.010_bib0010","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/leu.2015.69","article-title":"Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes","volume":"29","author":"Ga\u00f1\u00e1n-G\u00f3mez","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2026.05.010_bib0011","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2009.07593.x","article-title":"IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome","volume":"145","author":"Kordasti","year":"2009","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.clml.2026.05.010_bib0012","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1007\/s00018-015-1846-x","article-title":"The inflammatory microenvironment in MDS","volume":"72","author":"Yang","year":"2015","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"10.1016\/j.clml.2026.05.010_bib0013","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1182\/blood-2007-01-067546","article-title":"CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)","volume":"110","author":"Kordasti","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2026.05.010_bib0014","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.canep.2014.08.003","article-title":"Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the General Practice Research Database","volume":"38","author":"Wilson","year":"2014","journal-title":"Cancer Epidemiol"},{"issue":"7","key":"10.1016\/j.clml.2026.05.010_bib0015","first-page":"603","article-title":"Risk factors for myelodysplastic syndromes: a case-control study in Greece","volume":"13","author":"Dalamaga","year":"2002","journal-title":"Cancer Causes Control"},{"issue":"7","key":"10.1016\/j.clml.2026.05.010_bib0016","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1080\/10428194.2018.1542152","article-title":"Gastrointestinal Behcet's-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature review","volume":"60","author":"Wesner","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.clml.2026.05.010_bib0017","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3904\/kjim.2018.247","article-title":"Mutation of ten-eleven translocation-2 is associated with increased risk of autoimmune disease in patients with myelodysplastic syndrome","volume":"35","author":"Oh","year":"2020","journal-title":"Korean J Intern Med"},{"issue":"9","key":"10.1016\/j.clml.2026.05.010_bib0018","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1038\/s41375-021-01152-1","article-title":"Genomic landscape of MDS\/CMML associated with systemic inflammatory and autoimmune disease","volume":"35","author":"Zhao","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.05.010_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.610019","article-title":"Somatic mutations and the risk of undifferentiated autoinflammatory disease in MDS: an under-recognized but prognostically important complication","volume":"12","author":"Watad","year":"2021","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.clml.2026.05.010_bib0020","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2026.05.010_bib0021","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.05.010_bib0022","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and Guidelines for the interpretation and reporting of sequence variants in Cancer: a Joint consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"issue":"12","key":"10.1016\/j.clml.2026.05.010_bib0023","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2026.05.010_bib0024","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"17","key":"10.1016\/j.clml.2026.05.010_bib0025","first-page":"2047","article-title":"Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes","volume":"141","author":"Zeidan","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2026.05.010_bib0026","doi-asserted-by":"crossref","first-page":"E280","DOI":"10.1002\/ajh.24333","article-title":"Autoimmune diseases and myelodysplastic syndromes","volume":"91","author":"Komrokji","year":"2016","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.clml.2026.05.010_bib0027","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s00277-018-3302-0","article-title":"Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes","volume":"97","author":"Montoro","year":"2018","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.clml.2026.05.010_bib0028","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/acr.20504","article-title":"Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study","volume":"63","author":"de Hollanda","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"13","key":"10.1016\/j.clml.2026.05.010_bib0029","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003091","article-title":"Certain autoimmune manifestations are associated with distinctive karyotypes and outcomes in patients with myelodysplastic syndrome: a retrospective cohort study","volume":"95","author":"Lee","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.clml.2026.05.010_bib0030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0609.1995.tb00231.x","article-title":"Immune-mediated complications in patients with myelodysplastic syndromes\u2013clinical and cytogenetic features","volume":"55","author":"Billstr\u00f6m","year":"1995","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2026.05.010_bib0031","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/rheumatology\/kev294","article-title":"Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study","volume":"55","author":"Mekinian","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"22","key":"10.1016\/j.clml.2026.05.010_bib0032","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.1182\/bloodadvances.2023011050","article-title":"Impact of preexisting autoimmune disease on myelodysplastic syndromes outcomes: a population analysis","volume":"7","author":"Adrianzen-Herrera","year":"2023","journal-title":"Blood Adv"},{"issue":"27","key":"10.1016\/j.clml.2026.05.010_bib0033","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2026.05.010_bib0034","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.autrev.2011.12.005","article-title":"Cytokines and Behcet's disease","volume":"11","author":"Zhou","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.clml.2026.05.010_bib0035","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nri2094","article-title":"Cytokines in the pathogenesis of rheumatoid arthritis","volume":"7","author":"McInnes","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.clml.2026.05.010_bib0036","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/ard.2009.115378","article-title":"Cytokines in Sjogren's syndrome: potential therapeutic targets","volume":"69","author":"Roescher","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.clml.2026.05.010_bib0037","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2018-10-844654","article-title":"The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes","volume":"133","author":"Sallman","year":"2019","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:32:10Z","timestamp":1785907930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2152265026001643"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.05.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoimmune Features in Myelodysplastic Syndromes: Clinical and Molecular Heterogeneity With Integrated IPSS-M Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}